

Editorial Office  
*World Journal of Gastroenterology*

Dear Editor:

The enclosed manuscript entitled “**Immunotherapy in Human Colorectal Cancer: Challenges and Prospective**” has been revised according to the insightful suggestions of the reviewers and is hereby re-submitted for possible publication in the *World Journal of Gastroenterology*. A point-by-point reply to the reviewers’ comments follows.

Point-by-Point Reply to the Reviewer’s Comments (the reviewers’ comments are in bold):

**Reviewer’s code:** 00075352

**The authors submitted an interesting review regarding immunotherapy in Colorectal cancer; with thoughtful comments. The text is well written. In the introduction the authors confuse the treatment of colon cancer vs rectal cancer. They mentioned the neoadjuvant therapy which is accepted in locally advanced rectal cancer but not in colon cancer. They should correct this issue. In page 10, I am concern with the statement regarding the benefit of OncoVax in stage II of colon cancer. These patients have an excellent prognosis despite 20% develop recurrence. The authors should discuss this issue.**

**Response:** Thanks for the suggestion. We have revised it in the introduction section (page 4). Regarding OncoVax benefit, we also revised this section and added a recently published meta-analysis data (page 11).

**Reviewer’s code:** 01844002

**In their manuscript Sun et al. provides timely and comprehensive but concise review on immunotherapy for colorectal cancer. Generally the manuscript is well written and conceivable. However, limitations in addition to the mechanistic insights and/or a rationale behind each of type of immunotherapy are hopefully described before it acceptance.**

**Response:** Thanks for the suggestion. We have added brief paragraph in each type of immunotherapy to describe a rationale.

**Reviewer’s code:** 03508891

**The paper by Sun et al provides a good review of the current scenario in CRC immunotherapy. Only some minimal changes are needed: -The author should take into account that neoadjuvant treatment with radio/chemotherapy is valid option only for rectal cancer and not for colon cancer. Please better clarify this part in the introduction, where it seems that these options are valid for all CRC cancer. - In the section dedicated to CRC immunotherapy, the author should include a sub-paragraph**

**dedicated to chemoimmunotherapy, were Correale p et al published different phase 1-2 (including a combination of chemoimmunotherapy and cancer vaccine) and a phase 3 trial in colorectal cancer.**

**Response:** Thanks for the suggestion. We have revised this part in the introduction. As suggested by this reviewer, we also included chemoimmunotherapy in colorectal cancer (Page 12).

**Reviewer's code:** 00227359

**As a surgeon I learnt lots of things about the promising medical treatments of the CRCs. It summed up the update trials on the topic.**

**Response:** Thanks!

The authors thank the reviewers and editor for their critical evaluation of the data that were presented. We also thank the *World Journal of Gastroenterology* for the opportunity to submit this revised manuscript for the consideration of publication.

Sincerely,

Jun Yan, M.D., Ph.D.  
Professor and Endowed Chair  
Department of Medicine  
University of Louisville

